Is giant cell arteritis an infectious disease? Biological and epidemiological evidence

Presse Medicale

Volumn 33, Issue 19 II, 2004, Pages 1403-1408

  Duhaut, Pierre ^a   Bosshard, Sylvie ^b   Ducroix, Jean Pierre ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR4 ANTIGEN;

CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; EPSTEIN BARR VIRUS; GIANT CELL ARTERITIS; HEPATITIS B VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; PARAINFLUENZA VIRUS 1; PARVOVIRUS; POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; VARICELLA ZOSTER VIRUS; VIRUS INFECTION;

EID: 9144243577     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(04)98939-7     Document Type: Review

References (50)

1. Barrier J, Bignon J, Soulillou J, Grolleau J. Increased prevalence of HLA DR4 in giant cell arteritis. N Engl J Med 1981; 305: 104-5.
2. Lowenstein MB, Bridgeford PH, Vasy FB, Germain BF, Espinoza LR, Increased frequency of HLA DR3 and DR4 in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1983; 26: 925-7.
3. Armstrong RD, Behn A, Myles A, Panayi GS, Welsh KI. Histocompatibility antigens in polymyalgia rheumatica and giant cell arteritis. J Rheumatol 1983; 10: 659-61.
4. Hansen JA, Healy LA, Wilske KR, Association between giant cell (temporal) arteritis and HLA Cw3. Human Immunol 1985; 13: 193-8.
5. Calamia KT, Moore SB, Elveback LR, Hunder GG. HLA DR 4 locus antigen in polymyalgia rheumatica and giant cell arteritis. J Rheumatol 1981; 8: 993-6.
6. Cid MC, Ercilla G, Vilaseca J et al. Polymyalgia rheumatica: a syndrome associated with HLA-DR4 antigen. Arthritis Rheum 1998; 31: 678-82.
7. Richardson J, Gladman DD, Fam A, Keystone EC. HLA-DR4 in giant cell arteritis: association with polymyalgia rheumatica syndrome. Arthritis Rheum 1987; 30: 1293-7.
8. O'Brien JP, Vascular accidents after actinic (solar) exposure. An aspect of the temporal arteritis/polymyalgia rheumatica syndrome. Int J Dermatol 1987; 26: 366-70.
9. O'Brien JP. A new risk factor and other actinic radiation in giant cell arteritis and atherosclerosis. Int J Dermatol 1987; 26: 345-8.
10. Barrier J, Pion P, Massari R, Peltier P, Rojouan J, Grolleau JY, Approche épidémiologique de la maladie de Horton dans le département de Loire-Atlantique: 110 cas en 10 ans (1970-1979). Rev Med Interne 1982; 3: 13-20.
11. Machado EBV, Gabriel SE, Beard CM, Michet CJ, O'Fallon WM, Ballard DJ. A population-based case-control study of temporal arteritis: evidence for an association between temporal arteritis and degenerative vascular disease? Int J Epidemiol 1989; 18: 836-41.
12. Duhaut P, Pinède L, Demolombe-Ragué S et al. Giant cell arteritis and cardiovascular risk factors: a multicentric, prospective case-control study. Arthritis Rheum 1998; 4: 1960-5.
13. Duhaut P, Pinède L, Demolombe-Ragué S et al. Biopsy proven and negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Ann Rheum Dis 1999; 58: 335-41.
14. Bengtsson BA, Malmvall BE. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidence of different clinical presentations and eye complications. Arthritis Rheum 1981; 24: 899-904.
15. Russo MG, Waxman J, Abdoh AA, Serebro LH. Correlation between infection and the onset of the giant cell (temporal) arteritis syndrome. A trigger mechanism? Arthritis Rheum 1995; 38: 374-80.
16. Salvarani C, Gabriel SE, Balister M, Accardo S. Increased prevalence of giant cell arteritis in Olsmted County, Minnesota: apparent fluctuations in a cylic pattern, Ann Intern Med 1995; 123: 192-4.
17. Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996; 23: 112-19.
18. Reinhold-Keller E, Zeidler A, Gutfleisch J, Peter HH, Raspe HH, Gross WL. Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology 2000; 39: 1296-402.
19. Jonasson F, Cullen JF, Elton RA. Temporal arteritis. A 14-year epidemiological, clinical and pronostic study. Scott Med J 1979; 24: 111-17.
20. Friedman G, Friedman B, Benbassat J, Epidemiology of temporal arteritis in Israel. Israel J Med Sci 1982; 18: 241-4.
21. Petursdottir V, Johansson H, Nordborg E, Nordborg C. The epidemiology of biopsy-proven giant cell arteritis: special reference to cyclic fluctuations. Rheumatology 1999; 38: 1208-12.
22. Narvaez J, Clavaguera MT, Nolla-Sole JM, Valverde-Garcia J, Roig-Escofet D. Lack of association between infection and onset of polymyalgia rheumatica. J Rheumatol 2000; 27: 953-67.
23. Gonzalez-Gay MA, Garcia-Porrua C, Rivas MJ, Rodriguez-Ledo P, Llorca J. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over a 18-year period. Ann Rheum Dis 2001; 60: 367-71.
24. Mitschek G, Auböck L. La découverte d'inclusions cytoplasmiques d'allure virale dans l'artérite temporale (Maladie de Horton et Magath). Ann Anat Path 1973; 18: 449-58.
25. Gocke DJ, Hsu K, Morgan C, Bonbardieri S, Lockshin M, Christian CL. Association between polyarteritis and Australia antigen, Lancet 1970; 2: 1149-53.
26. Bacon PA, Doherty SM, Zuckerman AJ. Hepatitis-B antibody in polymyalgia rheumatica. Lancet 1975; 2: 476-8.
27. Liang M, Greenberg H, Pincus T, Robinson WS. Hepatitis-B antibody in polymyalgia rheumatica. Lancet 1976; 1: 43.
28. Plouvier B, Wattre P, Devulder B. HBs Ag in superficial artery of patient with polymyalgia rheumatica. Lancet 1978; 1: 933.
29. Bridgeford PH, Lowenstein M, Bocanegra TS, Vasey FB, Germain BF, Espinoza LR. Polymyalgia rheumatica and giant cell arteritis: histocompatibility typing and hepatitis-B infection studies. Arthritis Rheum 1980; 23: 516-8.
30. Elling H, Skinhoj P, Elling P. Hepatitis B virus and polymyalgia rheumatica: a search for HBsAg, HBsAb, HBeAg, and HBeAb. Ann Rheum Dis 1980; 39: 511-13.
31. Permin H, Aldershvile J, Nielsen JO. Hepatitis B virus infection in patients with rheumatic diseases. Ann Rheum Dis 1982; 41: 479-82.
32. Helweg-Larsen J, Tarp B, Obel N, Baslund B. No evidence of parvovirus B 19, Chlamydia pneumoniae or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritis. Rheumatology 2002; 41: 445-9.
33. Barrier JH, De Haldat de Lys F, Billaudel S, Peltier P, Ponge T. Herpes Zoster: serological study and cranial giant cell arteritis. J Rheumatol 1986; 13: 6-7.
34. Nordborg C Nordborg E, Petursdottir V et al. Search for varicella zoster in giant cell arteritis. Ann Neurol 1998; 44: 413-14.
35. Al-Abdulla NA, Rismondo V, Minkowski JS, Miller NR. Herpes zoster vasculitis presenting a giant cell arteritis with bilateral internuclear ophtalmologgia. Am J Ophthalmol 2002; 134: 912-914.
36. Buchwald D, Sullivan JL, Leddy S, Komaroff AL. "Chronic Epstein-Barr virus infection" syndrome and polymyalgia rheumatica. J Rheumatol 1988; 15: 479-82.
37. Fest T, Mougin C, Dupond JL. Giant cell arteritis, Ann Intern Med 1996; 124: 927-8.
38. Cimmino MA, Grazi G, Balistreri M, Accardo S, Increased prevalence of antibodies to adenovirus and respiratory syncytial virus in polymyalgia rheumatica. Clin Exp Rheumatol 1993; 11: 309-13.
39. Fontana PE, Gabutti L, Piffaretti JC, Marone C. Antibiotic treatment for giant cell arteritis? Lancet 1996; 348: 842-4.
40. Duhaut P, Bosshard S, Calvet A et al. Giant cell arteritis, polymyalgia rheumatica, and viral hypotheses: a multicentric, prospective case-control study. J Rheumatol 1999; 26: 61-9.
41. Boiardi L,Donati M, Macchioni PL et al. Increased prevalence of antibodies to paraininfluenza viruses in polymyalgia rheumatica: a case-control study. 1st International Conference on PMR/GCA, April 1999, Prato, Italy.
42. Gabriel SE, Espy M, Erdman DD, Bjornsson J, Smith TF, Hunder GG. The role of parvovirus B 19 in the pathogenesis of giant cell arteritis. A preliminary evaluation. Arthritis Rheum 1999; 42: 1255-8.
43. Salvarani C, Farnetti E, Casali B et al. Detection of parvovirus B19 DNA by polymerase chain reaction in giant cell arteritis: a case-control study. Arthritis Rheum 2002; 46: 3099-101.
44. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 2002; 288: 2724-31.
45. Wagner AD, Gerard HC, Fresemann T et al. Detection of Chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells. Arthritis Rheum 2000; 43: 1543-51.
46. Rimenti G, Blasi F, Cosentini R et al. Temporal arteritis associated with Chlamydia pneumoniae DNA detected in an artery specimen. J Rheumatol 2000; 27: 2718-20.
47. Bonnet F, Morlat P, Delevaux I et al. A possible association between Chlamydia psittacci infection and temporal arteritis. Joint Bone Spine 2000; 67: 550-2.
48. Regan MJ, Wood BJ, Hsieh YH et al. Temporal arteritis and chlamydia pneumoniae: failure to detect the organism by polymerase chain reaction in ninety cases and ninety controls. Arthritis Rheum 2002; 46: 1056-60.
49. Haugeberg G, Bie R, Mordbo SA. Chlamydia pneumoniae not detected in temporal artery biopsies from patients with temporal arteritis. Scand J Rheumatol 2000; 29: 127-8.
50. Weyand C, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003; 349: 1n60-9.